<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294619</url>
  </required_header>
  <id_info>
    <org_study_id>BPLG-005</org_study_id>
    <nct_id>NCT00294619</nct_id>
  </id_info>
  <brief_title>Treatment of Adults With Growth Hormone Deficiency</brief_title>
  <official_title>A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioPartners GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety profile of a new weekly
      administered growth hormone preparation compared with placebo in adults with growth hormone
      deficiency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Fat Mass at the end of 26-week treatment from baseline</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in the following parameters at the end of 26-week treatment from baseline; other body composition parameters, QoL Score, Serum IGF-I, IGFBP-3 levels &amp; SDS, Lipid profile, waist-to-hip ratio</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Pituitary Disorders</condition>
  <condition>Adult Growth Hormone Deficiency</condition>
  <arm_group>
    <arm_group_label>LB03002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>growth hormone</intervention_name>
    <description>subcutaneous injection, once-weekly</description>
    <arm_group_label>LB03002</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of at least 23 years and not more than 70 years of age

          -  GHD of either adult onset(AO)or Childhood onset(CO), either idiopathic or secondary to
             pituitary disease

          -  Confirmed diagnosis of GHD defined

          -  IGF-1 SDS â‰¤ -1 at screening

          -  No exposure to rhGH within the last 6 months

          -  Patients with adequate adrenal function, which is confirmed by ACTH stimulation test
             at screening; or Patients with known secondary hypoadrenalism on adequate
             glucocorticoid replacement therapy

          -  If applicable, hormone replacement therapies for any other hormone deficiencies,
             adequate and stable for at least 3 months before study entry

          -  Women of child-bearing potential to be using a reliable method of contraception at the
             screening and be willing to use it throughout the study

          -  A negative serum pregnancy test is required at screening for females of child-bearing
             potential.

        Exclusion Criteria:

          -  History of malignancy other than cranial tumor or leukemia causing GHD or fully
             treated basal cell carcinoma

          -  Evidence of active malignancy

          -  Evidence of growth of pituitary adenoma or other intracranial tumor within the last 12
             months, or patients without MRI or CT data to confirm the tumor stability within the
             last 12 months

          -  Significant hepatic dysfunction

          -  Chronic renal impairment

          -  Clinically significant pulmonary, cardiac, hepatic, renal, or neuromuscular disease

          -  Prader-Willi syndrome

          -  Acute severe illness in the last 6 months

          -  Benign intracranial hypertension

          -  Active Cushing's syndrome within the last 12 months

          -  Uncontrolled hypertension

          -  Patients with overt diabetes mellitus or evidence of persistent impaired glucose
             tolerance

          -  Severe psychiatric disease or patients who cannot understand the objective and methods
             of the study or patients with current alcohol abuse

          -  Pregnancy or lactation

          -  Known hypersensitivity to any ingredient of the study drug

          -  Inability to undergo scanning by dual-energy X ray absorptiometry (DXA) due to a body
             weight more than 130 kg or in situ internal or external devices known to interfere
             with DXA scanning

          -  Weight reducing drugs or appetite suppressants

          -  Anabolic steroids other than gonadal steroid replacement therapy within 2 months
             before study entry

          -  Methylphenidate within 2 months before study entry

          -  Systemic corticosteroids other than in replacement doses within the 3 months before
             study entry.

          -  History of non-compliance with medications, un-cooperativeness or drug abuse

          -  Patients participating in another study parallel to, or within 6 months prior to study
             entry, or previous participation in this study

          -  Patients who are not able to comply with the study protocol for any reason.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HJ Ji, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>LG Life Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2006</study_first_submitted>
  <study_first_submitted_qc>February 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2006</study_first_posted>
  <last_update_submitted>October 4, 2012</last_update_submitted>
  <last_update_submitted_qc>October 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Growth hormone deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocrine System Diseases</mesh_term>
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

